Adverse Reactions During Biological Therapy for Psoriasis: Results of a Survey of the Spanish Psoriasis Group

Arthritis possibly induced and exacerbated by a tumour necrosis factor antagonist in a patient with psoriasis vulgaris

“…In contrast, reports on arthritis induced or exacerbated by these agents are rare. Among a total of 988 Spanish patients with psoriasis treated with biologics, new‐onset PsA was observed in 5·8%, 0·55% and 0·45% of patients treated with efalizumab, infliximab and etanercept, respectively, while none of the patients on adalimumab developed arthritis . Three of 107 patients with rheumatoid arthritis receiving infliximab experienced exacerbation 3 months to 1 year after its initiation, and a dose increase resulted in deterioration .…”

“…Despite the widespread use of adalimumab, arthritis possibly induced by this biologic is quite rare in psoriasis (none reported in the large Spanish study mentioned earlier), which raises two important issues. The first is racial difference.…”

Subclinical cardiovascular disease and it's improvement after long‐term TNF‐α inhibitor therapy in severe psoriatic patients

“…In the field of psoriasis, only a few studies have been conducted. According to a Spanish research group who analysed data from 988 psoriatic patients treated with various biological therapies (including 682 patients treated with TNF‐α inhibitors), cardiac function declined in 0.2% of the etanercept‐, 1.1% of the infliximab‐ and 0% of the adalimumab‐treated patients who did not suffer from heart failure …”

Development of paradoxical inflammatory disorders during treatment of psoriasis with TNF inhibitors: a review of published cases

“…6,[16][17][18][19][20] Cassano et al 21 In two clinical trials, five patients developed palmoplantar pustulosis following either etanercept or adalimumab. 18,23 In one case report, a 48-year-old female developed palmoplantar pustular psoriasis, which did not improve despite cessation, and phototherapy was necessary to obtain remission. 24 New onset or exacerbation of psoriatic arthritis was described by Sanchez et al 23 …”

“…A total of three cases of unspecified demyelination following adalimumab were reported in one clinical trial and two case reports. 23,66 Soloman et al 67 reported a case of a 61-year-old female who, after 72 months of treatment with etanercept, developed a transverse myelitis followed by progressive multiple sclerosis. 23,66 Soloman et al 67 reported a case of a 61-year-old female who, after 72 months of treatment with etanercept, developed a transverse myelitis followed by progressive multiple sclerosis.…”